Entering text into the input field will update the search result below

Schrödinger inks multi-target drug discovery deal with Bristol-Myers Squibb

  • Schrödinger (NASDAQ:SDGR) jumps 7% premarket on collaboration with Bristol-Myers Squibb (NYSE:BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.
  • The collaboration includes two of Schrödinger’s early-stage programs and additional undisclosed targets.
  • Under the terms of the agreement, Bristol-Myers will pay $55M upfront, and

Recommended For You

Related Stocks

SymbolLast Price% Chg
BMY
--
SDGR
--